A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma
ID Number 15-1345Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to find the dose of the experimental drug, daratumumab, that would be best to use in future studies for the treatment of Smoldering Multiple Myeloma (SMM). The effects of SMM as well as any side effects will be explored.
Recruiting Patients: Yes